CoolSculpting Works Modestly. Its Worst Outcome Is the Opposite of the Goal.

What the procedure actually does

Cryolipolysis exploits a real and slightly odd piece of physiology: fat cells crystallise at temperatures that leave the skin, nerves and vessels above them unharmed. Cool a pocket of subcutaneous fat to the right range for long enough and the adipocytes undergo apoptosis, then get cleared over the following weeks by the body's ordinary inflammatory machinery. The visible result lags the treatment by two to three months because the clearance is the slow part.

The efficacy data is neither miraculous nor fake. A systematic review in Plastic and Reconstructive Surgery screened 319 articles and included nineteen clinical studies. Average reduction in caliper measurement ranged from 14.67% to 28.5%; average reduction measured by ultrasound ranged from 10.3% to 25.5%. Later reviews land in similar territory, with normalised fat-layer reductions around a fifth at two months and a quarter at six.

Those are percentages of the fat layer in the treated pocket, not of body fat, and the distinction matters enormously. A quarter of a pinchable roll is a change you can see in a mirror and frequently cannot see in clothes. Reviewers also found no significant impact on lipid levels or liver function tests in any study, which addresses the most common metabolic worry.

Who it suits follows directly: someone at a stable weight with a discrete, pinchable pocket that has not responded to anything else. It is not a weight-loss intervention, and it does nothing for skin laxity — if the concern is loose skin rather than volume, removing fat underneath it usually makes the laxity more obvious rather than less.

The complication, and how the number moved

Paradoxical adipose hyperplasia is what it sounds like. Instead of shrinking, the treated area enlarges — a firm, well-demarcated mass that typically conforms to the shape of the applicator, appearing weeks to months after treatment. It is painless, it is visually obvious, and it does not resolve on its own.

The interesting part is the epidemiology, because it is a case study in how a safety claim gets built and then revised.

That 2015 systematic review — the one establishing the efficacy figures above — noted that paradoxical adipose hyperplasia was described in one patient across the entire reviewed literature. One. That is the empirical basis on which the reassurance was originally constructed, and the manufacturer's quoted figure settled at 0.025%, roughly one per four thousand cycles.

Then real-world reporting accumulated. A multicentre evaluation across eight Canadian medical centres reviewed 8,658 treatment cycles in 2,114 patients and found incidence rates between 0.05% and 0.39% — the authors described these as slightly higher than the manufacturer's rate, which is generous, since the upper bound is more than fifteen times it. Of patients who developed PAH, 55% were male and 77.8% were of European ethnic origin.

And in 2025, a systematic review and meta-analysis pooled 28 studies covering 13,078 patients. The pooled incidence was 0.22%, with a confidence interval running from 0.10% to 0.47% — approximately one in 455. The authors' conclusion is worth quoting for its bluntness: the incidence of PAH following cryolipolysis appears to be higher than manufacturer reports, and the findings emphasise the need for comprehensive risk disclosure and improved adverse event reporting.

They also noted that only four of the 28 studies reported follow-up of sixteen weeks or longer — which, given that PAH typically declares itself months out, means the pooled figure is likely to be an underestimate rather than an overestimate.

The part that makes it genuinely bad

Rare complications are ordinary in medicine, and a rate around a fifth of one per cent would be unremarkable for many procedures. Two features make this one different.

The first is that the failure mode is the inverse of the goal. Someone pays for a smaller abdomen and acquires a larger, firmer, differently-shaped one. There is no partial credit and no version of the outcome that resembles what was purchased.

The second is the correction. PAH is not managed with a repeat session or a topical or time. It is corrected surgically — liposuction, sometimes with excision — and surgeons generally advise waiting for the tissue to mature before operating, which means living with it for months first. So the entire premise of the procedure, that it is the non-surgical option, inverts for the people who get this complication. They end up having the surgery they were trying to avoid, at their own cost, to fix a result they paid for.

There is a genuinely encouraging finding buried in the Canadian data, and it deserves equal weight: incidence at all sites fell by over 75% after newer device models were introduced, and 76.9% of cases were associated with older units. That is a real engineering improvement, not a marketing line. It is also a specific question worth asking at a consultation — which device generation, which applicator — because the risk is not uniform across equipment, and a clinic running older hardware is offering a materially different risk profile from one that is not.

The cost arithmetic that gets quoted one cycle at a time

The structural problem with how this procedure is sold is that the unit of pricing and the unit of result are different things.

A cycle treats one applicator-sized area. An abdomen is not one applicator-sized area — depending on anatomy it may be four, six or more placements to cover the region, and most areas need repeating to reach a visible endpoint, with published practice frequently describing two sessions per area as the realistic minimum. Multiply placements by sessions and the number a consultation opens with bears little relationship to what a completed plan costs.

This is not deceptive exactly; it is how the technology is billed. But it does mean the honest comparison is not one cycle against a surgical consultation. It is a full multi-session plan against liposuction, and at that scale the comparison stops being obvious.

Liposuction is more invasive, requires anaesthesia and recovery, and carries surgical risk. It also removes substantially more fat, does it in one intervention, and gives a surgeon direct control over contour rather than the shape of an applicator. Cryolipolysis buys convenience, no downtime and no anaesthesia, at the cost of a smaller and less predictable result across more appointments. Both are defensible choices. Only one of them is usually presented as the safe default, and that framing is doing work the evidence does not fully support.

How to consult, and what to do around it

If you are considering this, a few things move the odds and the outcome, none of them exotic.

Ask which device generation and applicator will be used, and ask directly what the clinic's own PAH rate has been — not the manufacturer's figure. Ask what happens if it occurs: who pays for the correction, whether there is a written policy, and whether the clinic has a relationship with a plastic surgeon. A clinic that has thought about this will answer straightforwardly. One that treats the question as hostile has told you something.

Photograph the area beforehand in consistent lighting and repeat monthly, because the change is slow and the eye is a poor instrument over three months in either direction. And set the endpoint in advance — how much change, by when — so that a modest but genuine result is recognised as a result rather than as a reason to buy more cycles. The Derm Visit Prep tool is a straightforward way to turn all of that into a page you actually take with you.

Aftercare is undramatic. The area is commonly numb, tender, swollen or bruised for one to several weeks, and occasionally there is a period of sharp neuropathic-type pain in the second week that resolves. Nothing topical accelerates fat clearance, and any product sold on that claim is selling you a massage. What is reasonable is keeping the skin comfortable with something bland — La Roche-Posay Lipikar AP+M Triple Repair Body Moisturizer or CeraVe Intensive Moisturizing Lotion are the unglamorous right answers, and Aveeno Daily Moisturizing Lotion does the same job.

One honest note on the laxity question, since it is the most common mismatch between what people want and what they book: if the real complaint is crepey or loose skin rather than volume, this is the wrong procedure, and so is any body lotion. A topical ↗retinoid like Paula's Choice RESIST Retinol Skin-Smoothing Body Treatment can improve surface texture over months, which is a real if modest effect and a completely different one from tightening. Being clear with yourself about which of the two you are actually bothered by is the single most useful thing you can do before any consultation.

Holding both facts at once

The fair summary is not that cryolipolysis is dangerous or that it is a scam. It is that it is a modestly effective procedure with a rare, genuinely bad, surgically-corrected failure mode whose incidence was understated for a decade and has been revised upward as independent data accumulated.

That pattern is worth recognising on its own terms, because it recurs across aesthetic medicine. Early efficacy trials are run and published by people with an interest in the outcome; complication rates depend on voluntary reporting by clinics with no incentive to report; and the correction arrives years later from independent reviewers pooling what actually happened. The people who said the quoted figure looked too clean were right, and saying so is not cynicism.

None of that means don't do it. A one-in-455 risk is one most people would accept for a result they want, and the improved device generations appear to have reduced it meaningfully. It means the number you price in should be the pooled one from independent review rather than the one on the brochure, and it means the question "what happens if this goes wrong, and who pays" belongs in the consultation rather than after it.